Skip to main content

Table 2 Clinical characteristics of participants

From: Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma

  Asthma (n = 93) COPD (n = 116) Total (n = 209)
Stable /AE status
 AE (%) 10 (10.8) 24 (20.9) 34 (16.3)
 Stable (%) 83 (89.2) 91 (79.1) 174 (83.7)
Newly diagnosed/follow-up patients
Newly-diagnosed (%) 41 (44.1) 36 (31.0) 77 (36.8)
Follow-up (%) 52 (55.9) 80 (69.0) 132 (63.2)
Number of acute exacerbations in the past year
 0 (%) 75 (80.6) 82 (70.7) 157 (75.1)
 1 (%) 10 (10.8) 18 (15.5) 28 (13.4)
 2 (%) 3 (3.2) 7 (6.0) 10 (4.8)
 ≥ 3 (%) 5 (5.4) 9 (7.8) 14 (6.7)
Pulmonary function
 FEV1 (L), mean ± SD 2.3 ± 0.8 1.4 ± 0.6 1.8 ± 0.8
 FEV1, %predicted, mean ± SD 81.5 ± 21.4 51.7 ± 22.0 65.5 ± 26.3
 FEV1/FVC, mean ± SD 74.4 ± 10.9 55.7 ± 11.6 64.3 ± 14.6
 PEF (L), mean ± SD 5.9 ± 1.9 4.0 ± 1.8 4.9 ± 2.1
 IC (L), mean ± SD 2.3 ± 0.6 2.0 ± 0.7 2.1 ± 0.7
 RV/TLC, mean ± SD 43.1 ± 9.0 51.0 ± 9.8 47.3 ± 10.2
GOLD
 I (%) / 12 (14.5) /
 II (%) / 23 (27.7) /
 III (%) / 36 (43.4) /
 IV (%) / 12 (14.5) /
Severity of asthma
 Mild and moderate asthma (%) 86 (92.5) / /
 Severe asthma (%) 7 (7.5) / /
Control of asthma
 Well and partly controlled (%) 83 (89.2) / /
 Uncontrolled (%) 10 (10.8) / /
 CAT, mean ± SD / 10.5 ± 6.5 /
 mMRC, mean ± SD 0.4 ± 0.7 1.2 ± 1.0 0.8 ± 0.9
  1. Data are shown as means ± standard deviation or number (%) patients
  2. COPD, chronic obstructive pulmonary disease; AE, acute exacerbation; FEV1, forced expiratory volume in 1 s; FEV1%, FEV1/predicted FEV1; FEV1/FVC, forced expiratory volume in 1 s/forced vital capacity; PEF, peak expiratory flow; IC, inspiratory capacity; RV/TLC, residual volume/total lung capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease; CAT, COPD Assessment Test; mMRC, Medical Research Council Dyspnea Scale